Literature DB >> 30946148

Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.

Ross S Milne1, Rachel A Silverman2,3, Ingrid A Beck1, Jennifer Mckernan-Mullin1, Wenjie Deng4, Thomas R Sibley4, Sandra Dross5, James N Kiarie6, Samah R Sakr7, Robert W Coombs5,8, Michael H Chung2,3,8, Lisa M Frenkel1,3,5,8,9.   

Abstract

OBJECTIVES: Among women initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based-ART with and without a history of single-dose nevirapine (sdNVP) with or without zidovudine with or without lamivudine (ZDV with and without 3TC) for prevention of mother-to-child HIV transmission (PMTCT), we hypothesized that pre-ART HIV-drug resistance would be associated with virologic failure DESIGN/
METHODS: : In a prospectively enrolled study, three genotypic drug-resistance assays [oligonucleotide-ligation-assay (OLA), consensus sequencing, and next-generation sequencing by Illumina] were retrospectively performed to detect pre-ART drug resistance. Minority or majority drug-resistant variants identified in pre-ART RNA and/or DNA, a history of antiretrovirals for PMTCT, and other risk factors were assessed for association with virologic failure.
RESULTS: Failure occurred in 38/169 (22.5%) women, and was associated with pre-ART drug resistance detected by any assay (OLA of plasma or PBMC, consensus sequencing of PBMC and/or plasma, and next-generation sequencing of PBMC at frequencies of at least 10% and as minority variants; all P < 0.0001). Failure was also associated with PMTCT using sdNVP and ZDV with or without 3TC, but not sdNVP only; however, the longer time-interval between PMTCT and ART initiation observed for sdNVP-only women showed no interaction with failure. Viral loads and OLA of PBMC in longitudinal specimens demonstrated rapid failure and emergence of drug resistance, particularly among sdNVP and ZDV with or without 3TC-experienced women with pre-ART drug-resistant minority variants by next-generation sequencing but without drug resistance by OLA or consensus sequencing.
CONCLUSION: Pre-ART drug resistance was detected similarly by OLA of PBMC or plasma and by consensus sequencing, and was associated with virologic failure soon after initiation of first-line NVP-based ART. A history of sdNVP and ZDV with or without 3TC for PMTCT or minority variants detected by next-generation sequencing identified additional women with failure. These findings emphasize the value of assessing individual antiretroviral history, particularly nonsuppressive antiretrovirals with at least two drug classes, and testing for pre-ART drug resistance, including minority variants.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30946148      PMCID: PMC6635101          DOI: 10.1097/QAD.0000000000002134

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  43 in total

1.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

2.  Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.

Authors:  Karin J Metzner; Pia Rauch; Patrick Braun; Heribert Knechten; Robert Ehret; Klaus Korn; Rolf Kaiser; Nadine Sichtig; Britta Ranneberg; Jan van Lunzen; Hauke Walter
Journal:  J Clin Virol       Date:  2010-11-04       Impact factor: 3.168

3.  Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

Authors:  P Richard Harrigan; Robert S Hogg; Winnie W Y Dong; Benita Yip; Brian Wynhoven; Justin Woodward; Chanson J Brumme; Zabrina L Brumme; Theresa Mo; Chris S Alexander; Julio S G Montaner
Journal:  J Infect Dis       Date:  2004-12-22       Impact factor: 5.226

4.  Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing.

Authors:  Ingrid A Beck; Wenjie Deng; Rachel Payant; Robert Hall; Roger E Bumgarner; James I Mullins; Lisa M Frenkel
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

5.  Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.

Authors:  Rachel A Silverman; Ingrid A Beck; Catherine Kiptinness; Molly Levine; Ross Milne; Christine J McGrath; Steve Bii; Barbra A Richardson; Grace John-Stewart; Bhavna Chohan; Samah R Sakr; James N Kiarie; Lisa M Frenkel; Michael H Chung
Journal:  J Infect Dis       Date:  2017-12-19       Impact factor: 5.226

6.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

7.  Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program.

Authors:  Michael H Chung; Alison L Drake; Barbra A Richardson; Ashok Reddy; Joan Thiga; Samah R Sakr; James N Kiarie; Paul Yowakim; Grace C John-Stewart
Journal:  Curr HIV Res       Date:  2009-07       Impact factor: 1.581

8.  Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.

Authors:  Ingeborg Wijting; Casper Rokx; Charles Boucher; Jeroen van Kampen; Suzan Pas; Theodora de Vries-Sluijs; Carolina Schurink; Hannelore Bax; Maarten Derksen; Eleni-Rosalina Andrinopoulou; Marchina van der Ende; Eric van Gorp; Jan Nouwen; Annelies Verbon; Wouter Bierman; Bart Rijnders
Journal:  Lancet HIV       Date:  2017-10-26       Impact factor: 12.767

9.  Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.

Authors:  Ravindra K Gupta; Michael R Jordan; Binta J Sultan; Andrew Hill; Daniel H J Davis; John Gregson; Anthony W Sawyer; Raph L Hamers; Nicaise Ndembi; Deenan Pillay; Silvia Bertagnolio
Journal:  Lancet       Date:  2012-07-23       Impact factor: 79.321

10.  Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.

Authors:  Anne Derache; Collins C Iwuji; Kathy Baisley; Siva Danaviah; Anne-Geneviève Marcelin; Vincent Calvez; Tulio de Oliveira; François Dabis; Kholoud Porter; Deenan Pillay
Journal:  Clin Infect Dis       Date:  2019-07-02       Impact factor: 9.079

View more
  7 in total

1.  Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.

Authors:  Herbert A Mbunkah; Silvia Bertagnolio; Raph L Hamers; Gillian Hunt; Seth Inzaule; Tobias F Rinke De Wit; Roger Paredes; Neil T Parkin; Michael R Jordan; Karin J Metzner
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

2.  HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.

Authors:  William L Trebelcock; Javier R Lama; Ann Duerr; Hugo Sanchez; Robinson Cabello; Trupti Gilada; Patricia Segura; Sari L Reisner; Kenneth H Mayer; James Mullins; Rachel A Bender Ignacio
Journal:  J Int AIDS Soc       Date:  2019-11       Impact factor: 5.396

3.  Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.

Authors:  Ingrid A Beck; Molly Levine; Christine J McGrath; Steve Bii; Ross S Milne; James M Kingoo; Isaac So; Nina Andersen; Sandra Dross; Robert W Coombs; James Kiarie; Bhavna Chohan; Samah R Sakr; Michael H Chung; Lisa M Frenkel
Journal:  EClinicalMedicine       Date:  2020-01-14

4.  Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.

Authors:  Rosa Marlene Cuco; Osvaldo Loquiha; Adelino Juga; Aleny Couto; Bindiya Meggi; Adolfo Vubil; Esperança Sevene; Nafissa Osman; Marleen Temermam; Olivier Degomme; Mohsin Sidat; Nilesh Bhatt
Journal:  PLoS One       Date:  2022-02-10       Impact factor: 3.240

5.  Two strains and drug adherence: An HIV model in the paradigm of community transmission.

Authors:  Ashish Poonia; Siddhartha P Chakrabarty
Journal:  Nonlinear Dyn       Date:  2022-03-11       Impact factor: 5.741

Review 6.  Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations.

Authors:  Santiago Ávila-Ríos; Neil Parkin; Ronald Swanstrom; Roger Paredes; Robert Shafer; Hezhao Ji; Rami Kantor
Journal:  Viruses       Date:  2020-06-05       Impact factor: 5.048

7.  Cost analysis of implementing HIV drug resistance testing in Kenya: a case study of a service delivery site at a tertiary level hospital in Kenya.

Authors:  Rachael W Gachogo; Daniel N Mwai; Frank G Onyambu
Journal:  F1000Res       Date:  2020-07-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.